BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling ...

BNT327/ PM8002, an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization being developed in collaboration with Biotheus: For more information, please ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.

BioNTech's first late-stage cancer trial success Phase III trial shows BNT323 slows HER2-positive breast cancer progression, companies say Companies compete with AstraZeneca-Daiichi alliance For COVID ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BioNTech said Thursday it would buy CureVac, its onetime competitor in ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is eying a 2025 regulatory filing for what could become its first approved cancer ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese phase 2 ...